



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

25 April 2025
EMA/CHMP/125193/2025
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Calquence acalabrutinib

On 25 April 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Calquence. The marketing authorisation holder for this medicinal product is AstraZeneca AB.

The CHMP adopted a new indication to include treatment of adults with previously untreated chronic lymphocytic leukaemia in combination with venetoclax. The full indications for Calquence will therefore be as follows:²

Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Calquence in combination with venetoclax with or without obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² New text in bold

